Shopping Cart 0
Cart Subtotal
USD 0

Sicca Syndrome (Sjogren)-Pipeline Review, H2 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Sicca Syndrome (Sjogren)-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Sicca Syndrome (Sjogren)-Pipeline Review, H2 2017, provides an overview of the Sicca Syndrome (Sjogren) (Immunology) pipeline landscape.

Sjogren's syndrome is an autoimmune disease. It involves inflammation of glands and other tissues of the body. Symptoms include skin rashes or dry skin, vaginal dryness, persistent dry cough, prolonged fatigue, dry eye, dry mouth, joint pain, swelling and stiffness. Predisposing factors include age, sex and rheumatic disease.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Sicca Syndrome (Sjogren)-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Sicca Syndrome (Sjogren) (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Sicca Syndrome (Sjogren) (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Sicca Syndrome (Sjogren) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 12, 3, 7 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Sicca Syndrome (Sjogren) (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct'sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Sicca Syndrome (Sjogren) (Immunology).

The pipeline guide reviews pipeline therapeutics for Sicca Syndrome (Sjogren) (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Sicca Syndrome (Sjogren) (Immunology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Sicca Syndrome (Sjogren) (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Sicca Syndrome (Sjogren) (Immunology)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Sicca Syndrome (Sjogren) (Immunology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it'smost promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Sicca Syndrome (Sjogren) (Immunology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Sicca Syndrome (Sjogren)-Overview

Sicca Syndrome (Sjogren)-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Sicca Syndrome (Sjogren)-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Sicca Syndrome (Sjogren)-Companies Involved in Therapeutics Development

Akari Therapeutics Plc

Amgen Inc

Atlantic Bio Sci LLC

Bristol-Myers Squibb Co

Eli Lilly and Co

F. Hoffmann-La Roche Ltd

Galapagos NV

Gilead Sciences Inc

GlaxoSmithKline Plc

Immunwork Inc

MedImmune LLC

MimeTech Srl

Novartis AG

Ono Pharmaceutical Co Ltd

Samjin Pharm Co Ltd

UCB SA

XTL Biopharmaceuticals Ltd

Sicca Syndrome (Sjogren)-Drug Profiles

abatacept-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ABS-11-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AMG-557-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

belimumab-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

belimumab + rituximab-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for Type 1 Diabetes and Sjogrens Syndrome-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CFZ-533-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Coversin-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

edratide-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

filgotinib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GS-9876-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMSO-001-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

leniolisib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-3090106-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MEDI-4920-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MEDI-7734-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MT-8-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RG-7625-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RSLV-132-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SA-001-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

seletalisib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TE-2324-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tirabrutinib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VAY-736-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VM-200-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Sicca Syndrome (Sjogren)-Dormant Projects

Sicca Syndrome (Sjogren)-Discontinued Products

Sicca Syndrome (Sjogren)-Product Development Milestones

Featured News & Press Releases

Sep 12, 2017: XTL Biopharmaceuticals Unveils Additional Expanded hCDR1 Preclinical Data for the Treatment of Sjogren's Syndrome

Apr 05, 2017: XTL Biopharmaceuticals Unveils Expanded hCDR1 Preclinical Data for the Treatment of Sjogren'sSyndrome

Apr 04, 2017: Galapagos announces three new Phase 2 Proof-of-Concept studies with filgotinib

Feb 13, 2017: XTL Biopharmaceuticals Expands Clinical Advisory Board to Support Phase II Study of HCDR1 in Sjogren's Syndrome

Jan 05, 2017: XTL Biopharmaceuticals' Preclinical Studies of hCDR1 Demonstrate Therapeutic Potential In the Treatment of Sjogren's Syndrome

Apr 22, 2011: Breakthrough study links Type 1 diabetes and Sjogren'ssyndrome

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Sicca Syndrome (Sjogren), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development for Sicca Syndrome (Sjogren), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Sicca Syndrome (Sjogren)-Pipeline by Akari Therapeutics Plc, H2 2017

Sicca Syndrome (Sjogren)-Pipeline by Amgen Inc, H2 2017

Sicca Syndrome (Sjogren)-Pipeline by Atlantic Bio Sci LLC, H2 2017

Sicca Syndrome (Sjogren)-Pipeline by Bristol-Myers Squibb Co, H2 2017

Sicca Syndrome (Sjogren)-Pipeline by Eli Lilly and Co, H2 2017

Sicca Syndrome (Sjogren)-Pipeline by F. Hoffmann-La Roche Ltd, H2 2017

Sicca Syndrome (Sjogren)-Pipeline by Galapagos NV, H2 2017

Sicca Syndrome (Sjogren)-Pipeline by Gilead Sciences Inc, H2 2017

Sicca Syndrome (Sjogren)-Pipeline by GlaxoSmithKline Plc, H2 2017

Sicca Syndrome (Sjogren)-Pipeline by Immunwork Inc, H2 2017

Sicca Syndrome (Sjogren)-Pipeline by MedImmune LLC, H2 2017

Sicca Syndrome (Sjogren)-Pipeline by MimeTech Srl, H2 2017

Sicca Syndrome (Sjogren)-Pipeline by Novartis AG, H2 2017

Sicca Syndrome (Sjogren)-Pipeline by Ono Pharmaceutical Co Ltd, H2 2017

Sicca Syndrome (Sjogren)-Pipeline by Samjin Pharm Co Ltd, H2 2017

Sicca Syndrome (Sjogren)-Pipeline by UCB SA, H2 2017

Sicca Syndrome (Sjogren)-Pipeline by XTL Biopharmaceuticals Ltd, H2 2017

Sicca Syndrome (Sjogren)-Dormant Projects, H2 2017

Sicca Syndrome (Sjogren)-Discontinued Products, H2 2017

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies


Companies

Akari Therapeutics Plc

Amgen Inc

Atlantic Bio Sci LLC

Bristol-Myers Squibb Co

Eli Lilly and Co

F. Hoffmann-La Roche Ltd

Galapagos NV

Gilead Sciences Inc

GlaxoSmithKline Plc

Immunwork Inc

MedImmune LLC

MimeTech Srl

Novartis AG

Ono Pharmaceutical Co Ltd

Samjin Pharm Co Ltd

UCB SA

XTL Biopharmaceuticals Ltd

Sicca Syndrome (Sjogren)-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Sicca Syndrome (Sjogren)-Pipeline Review, H2 2017, provides an overview of the Sicca Syndrome (Sjogren) (Immunology) pipeline landscape.

Sjogren's syndrome is an autoimmune disease. It involves inflammation of glands and other tissues of the body. Symptoms include skin rashes or dry skin, vaginal dryness, persistent dry cough, prolonged fatigue, dry eye, dry mouth, joint pain, swelling and stiffness. Predisposing factors include age, sex and rheumatic disease.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Sicca Syndrome (Sjogren)-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Sicca Syndrome (Sjogren) (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Sicca Syndrome (Sjogren) (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Sicca Syndrome (Sjogren) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 12, 3, 7 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Sicca Syndrome (Sjogren) (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct'sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Sicca Syndrome (Sjogren) (Immunology).

The pipeline guide reviews pipeline therapeutics for Sicca Syndrome (Sjogren) (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Sicca Syndrome (Sjogren) (Immunology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Sicca Syndrome (Sjogren) (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Sicca Syndrome (Sjogren) (Immunology)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Sicca Syndrome (Sjogren) (Immunology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it'smost promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Sicca Syndrome (Sjogren) (Immunology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Sicca Syndrome (Sjogren)-Overview

Sicca Syndrome (Sjogren)-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Sicca Syndrome (Sjogren)-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Sicca Syndrome (Sjogren)-Companies Involved in Therapeutics Development

Akari Therapeutics Plc

Amgen Inc

Atlantic Bio Sci LLC

Bristol-Myers Squibb Co

Eli Lilly and Co

F. Hoffmann-La Roche Ltd

Galapagos NV

Gilead Sciences Inc

GlaxoSmithKline Plc

Immunwork Inc

MedImmune LLC

MimeTech Srl

Novartis AG

Ono Pharmaceutical Co Ltd

Samjin Pharm Co Ltd

UCB SA

XTL Biopharmaceuticals Ltd

Sicca Syndrome (Sjogren)-Drug Profiles

abatacept-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ABS-11-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AMG-557-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

belimumab-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

belimumab + rituximab-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for Type 1 Diabetes and Sjogrens Syndrome-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CFZ-533-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Coversin-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

edratide-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

filgotinib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GS-9876-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMSO-001-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

leniolisib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-3090106-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MEDI-4920-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MEDI-7734-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MT-8-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RG-7625-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RSLV-132-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SA-001-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

seletalisib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TE-2324-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tirabrutinib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VAY-736-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VM-200-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Sicca Syndrome (Sjogren)-Dormant Projects

Sicca Syndrome (Sjogren)-Discontinued Products

Sicca Syndrome (Sjogren)-Product Development Milestones

Featured News & Press Releases

Sep 12, 2017: XTL Biopharmaceuticals Unveils Additional Expanded hCDR1 Preclinical Data for the Treatment of Sjogren's Syndrome

Apr 05, 2017: XTL Biopharmaceuticals Unveils Expanded hCDR1 Preclinical Data for the Treatment of Sjogren'sSyndrome

Apr 04, 2017: Galapagos announces three new Phase 2 Proof-of-Concept studies with filgotinib

Feb 13, 2017: XTL Biopharmaceuticals Expands Clinical Advisory Board to Support Phase II Study of HCDR1 in Sjogren's Syndrome

Jan 05, 2017: XTL Biopharmaceuticals' Preclinical Studies of hCDR1 Demonstrate Therapeutic Potential In the Treatment of Sjogren's Syndrome

Apr 22, 2011: Breakthrough study links Type 1 diabetes and Sjogren'ssyndrome

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Sicca Syndrome (Sjogren), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development for Sicca Syndrome (Sjogren), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Sicca Syndrome (Sjogren)-Pipeline by Akari Therapeutics Plc, H2 2017

Sicca Syndrome (Sjogren)-Pipeline by Amgen Inc, H2 2017

Sicca Syndrome (Sjogren)-Pipeline by Atlantic Bio Sci LLC, H2 2017

Sicca Syndrome (Sjogren)-Pipeline by Bristol-Myers Squibb Co, H2 2017

Sicca Syndrome (Sjogren)-Pipeline by Eli Lilly and Co, H2 2017

Sicca Syndrome (Sjogren)-Pipeline by F. Hoffmann-La Roche Ltd, H2 2017

Sicca Syndrome (Sjogren)-Pipeline by Galapagos NV, H2 2017

Sicca Syndrome (Sjogren)-Pipeline by Gilead Sciences Inc, H2 2017

Sicca Syndrome (Sjogren)-Pipeline by GlaxoSmithKline Plc, H2 2017

Sicca Syndrome (Sjogren)-Pipeline by Immunwork Inc, H2 2017

Sicca Syndrome (Sjogren)-Pipeline by MedImmune LLC, H2 2017

Sicca Syndrome (Sjogren)-Pipeline by MimeTech Srl, H2 2017

Sicca Syndrome (Sjogren)-Pipeline by Novartis AG, H2 2017

Sicca Syndrome (Sjogren)-Pipeline by Ono Pharmaceutical Co Ltd, H2 2017

Sicca Syndrome (Sjogren)-Pipeline by Samjin Pharm Co Ltd, H2 2017

Sicca Syndrome (Sjogren)-Pipeline by UCB SA, H2 2017

Sicca Syndrome (Sjogren)-Pipeline by XTL Biopharmaceuticals Ltd, H2 2017

Sicca Syndrome (Sjogren)-Dormant Projects, H2 2017

Sicca Syndrome (Sjogren)-Discontinued Products, H2 2017

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Companies

Akari Therapeutics Plc

Amgen Inc

Atlantic Bio Sci LLC

Bristol-Myers Squibb Co

Eli Lilly and Co

F. Hoffmann-La Roche Ltd

Galapagos NV

Gilead Sciences Inc

GlaxoSmithKline Plc

Immunwork Inc

MedImmune LLC

MimeTech Srl

Novartis AG

Ono Pharmaceutical Co Ltd

Samjin Pharm Co Ltd

UCB SA

XTL Biopharmaceuticals Ltd